Trial
NCT02273752
Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Emory University
Collaborators
Novartis
Condition
Estrogen Receptor-positive Breast Cancer
Intervention
Everolimus
Why stopped
Slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-02-03